514. Nirmatrelvir/ritonavir or Molnupiravir for Treatment of Non-hospitalized Patients with COVID-19 at Risk of Disease Progression

BACKGROUND: In randomized controlled trials, Nirmatrelvir/ritonavir (NMV/r) and Molnupiravir (MPV) reduced the risk of severe/fatal COVID-19 disease. Real-world data are limited, particularly studies directly comparing the two agents. METHODS: Using the VA National COVID-19 database, we identified p...

Descripción completa

Detalles Bibliográficos
Autores principales: Butt, Adeel A, Yan, Peng, Shaikh, Obaid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677091/
http://dx.doi.org/10.1093/ofid/ofad500.583

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677091/
http://dx.doi.org/10.1093/ofid/ofad500.583

Ejemplares similares